Skip to main content

Advertisement

SpringerLink
Log in

Drug Therapy for Gynaecological Cancer in Older Women

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

A substantial proportion of all women dying from gynaecological malignancies are aged >75 years. Many reports have indicated that the survival of these patients is decreased compared with younger patients. Differences in biological behaviour, stage of the disease at presentation, and reluctance to undergo aggressive treatment with its associated morbidity are among the factors thought to be responsible for this difference in outcomes. However, investigations also indicate that elderly patients may receive less surgical and chemotherapeutic treatment without obvious clinical rationale. This overview is aimed at providing a guideline of chemotherapy appropriate for patients with epithelial ovarian, uterine (corpus and cervix), and vulvar cancer, aged 70 to 75 years and over.

Platinum-based chemotherapy is the cornerstone of drug treatment in patients with ovarian cancer. Patients aged between 70 and 75 years with a good performance status can be treated with cisplatin- or carboplatin-based chemotherapy. Carboplatin, either in combination or as a single-agent, may offer advantages in patients aged >75 years and in those with a poor performance status. For patients with early recurrence there is no standard treatment, but several cytostatic and hormonal agents can be used with palliative intent. Patients with a late recurrence are probably best retreated with a platinum-based regimen.

In metastatic endometrial cancer, hormonal therapy is the first choice in tumours expressing a progesterone receptor. Poorly differentiated tumours infrequently respond to endocrine therapy. In this situation, and for patients with tumours that have become resistant to hormonal manipulation, platinum-based chemotherapy may be used. The use of carboplatin-based regimens seems preferable in elderly patients, particularly in those with a decreased performance status.

The usefulness of chemotherapy in elderly patients with cervical cancer is limited. In case of recurrent or metastatic disease, the use of single agent (low-dose) cisplatin should be balanced against best supportive care. Although overall chemoradiation seems superior than radiotherapy alone in patients with locally advanced cervical cancer, the feasibility of this approach in elderly patients needs further investigation. Chemoradiation might also be considered in patients with locally advanced vulvar cancer. However, treatment-related morbidity can be considerable and randomised studies are lacking to prove a survival benefit.

Our understanding of the tolerance and effectiveness of chemotherapy in elderly patients is still incomplete due to a paucity of trials that specifically focus on this subset of patients. However, there appears no argument to withhold chemotherapy based purely on age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Visser O, Coebergh JWW, Schouten LJ, et al., editors. Incidence of cancer in The Netherlands 1995. Utrecht: Association of Comprehensive Cancer Centres, 1998

    Google Scholar 

  2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80: 1273–83

    PubMed  CAS  Google Scholar 

  3. Kennedy AW, Flagg JS, Webster KD. Gynecologic cancer in the very elderly. Gynecol Oncol 1989; 32(1): 49–54

    PubMed  CAS  Google Scholar 

  4. Grover SA, Cook EF, Adam J, et al. Delayed diagnosis of gynecologic tumors in elderly women: relation to national medical practice patterns. Am J Med 1989; 86(2): 151–7

    PubMed  CAS  Google Scholar 

  5. Yancik R, Ries L, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology, and end results program data. Am J Obstet Gynecol 1986; 154(3): 639–47

    PubMed  CAS  Google Scholar 

  6. Hightower RD, Nguyen HN, Averette HE, et al. National survey of ovarian carcinoma IV: patterns of care and related survival for older patients. Cancer 1994; 73(2): 377–83

    PubMed  CAS  Google Scholar 

  7. De Rijke JM, Schouten LJ, Schouten HC, et al. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 1996; 7: 677–85

    PubMed  Google Scholar 

  8. Balvert-Locht HR, Coebergh JWW. Gynecologic malignancies. In: Coebergh JWW, van der Heijden LH, Janssen-Heijden MLG, editors. Cancer incidence and survival in the Southeast of the Netherlands 1955–1994. Eindhoven: Comprehensive Cancer Centre South, 1995: 62–3

    Google Scholar 

  9. Ries LA. Ovarian cancer. Survival and treatment differences by age. Cancer 1993; 71: 524–9

    PubMed  CAS  Google Scholar 

  10. Yancik R, Ries LG. Cancer in the aged: an epidemiologic perspective on treatment issues. Cancer 1991; 68: 2502–10

    PubMed  CAS  Google Scholar 

  11. Santariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104–10

    Google Scholar 

  12. Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83

    PubMed  CAS  Google Scholar 

  13. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123–34

    PubMed  CAS  Google Scholar 

  14. Inouye SK, Peduzzi PN, Robinson JT, et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998; 279: 1187–93

    PubMed  CAS  Google Scholar 

  15. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 1986; 4: 702–9

    PubMed  CAS  Google Scholar 

  16. Melzer D, Mc Williams B, Brayne C, et al. Profile of disability in elderly people: estimates from a longitudinal population study. Medical Research Council cognitive function and ageing study (MRC CFAS) and resource implications study (RIS MRC CFAS). BMJ 1999; 318: 1108–11

    PubMed  CAS  Google Scholar 

  17. Ell K, Nishimoto R, Mediansky L, et al. Social relations, social support and survival among patients with cancer. J Psycho-som Res 1992; 36: 531–41

    CAS  Google Scholar 

  18. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and fuctional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582–7

    PubMed  CAS  Google Scholar 

  19. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996; 77: 395–401

    PubMed  CAS  Google Scholar 

  20. Extermann M, Balducci L. Practical proposals for clinical protocols in elderly patients with cancer. In: Balducci L, Lyman GH, Erschler WB, editors. Comprehensive geriatric oncology. 2nd ed. Amsterdam: Harwood Academic Publishers, 1998: 263–9

    Google Scholar 

  21. McKenna RJ. Clinical aspects of cancer in the elderly: treatment decisions, treatment choices, and follow-up. Cancer 1994; 74: 2107–17

    PubMed  Google Scholar 

  22. Balducci L, Phillips DM, Davis KM, et al. Systemic treatment of cancer in the elderly. Arch Gerontol Geriatr 1988; 7: 119–50

    PubMed  CAS  Google Scholar 

  23. Soteniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331–9

    Google Scholar 

  24. Raghaven D, Findlay MPN, McNeil EB. Cancer in the elderly. In: Peckham M, Pinedo HM, Veronesi U, editors: Oxford textbook of oncology. Oxford: Oxford University Press, 1995: 2169–89

    Google Scholar 

  25. Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20(1): 43–9

    PubMed  CAS  Google Scholar 

  26. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997; 80: 1317–22

    PubMed  CAS  Google Scholar 

  27. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–7

    Google Scholar 

  28. Stein BN, Petrelli NJ, Douglas HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: analysis of a large scale phase III trial. Cancer 1995; 75: 11–7

    PubMed  CAS  Google Scholar 

  29. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 5–27

    PubMed  CAS  Google Scholar 

  30. Marchetti DL, Lele SB, Priore RL, et al. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 1993; 49(1): 86–91

    PubMed  CAS  Google Scholar 

  31. Gershenson DM, Mitchell MF, Atkinson N, et al. Age contrasts in patients with advanced epithelial ovarian cancer: the M. D. Anderson Cancer Center experience. Cancer 1993; 71(2 Suppl.): 638–43

    PubMed  CAS  Google Scholar 

  32. de Rijke JM, Schouten LJ, van der Putten HWHM. Age-specific differences in treatment and survival of ovarian cancer patients in the province of Limburg, the Netherlands, 1986–1992. Int J Gynecol Cancer 1998; 8: 150–7

    Google Scholar 

  33. Levi F, Francheschi S, La Vecchia C, et al. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 1993; 4: 289–94

    PubMed  CAS  Google Scholar 

  34. Högberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993; 48: 38–49

    PubMed  Google Scholar 

  35. Oncology Committee of the International Federation of Gynecologists and Obstetricians (FIGO). Changes in definition of clinical staging for carcinoma of the cervix and ovary. Obstet Gynecol 1987; 70: 138

    Google Scholar 

  36. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993; 71: 517–23

    PubMed  CAS  Google Scholar 

  37. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413–20

    PubMed  CAS  Google Scholar 

  38. Heintz APM, van Oosterom AT, Trimbos JB, et al. The treatment of advanced ovarian carcinoma (1): clinical variables associated with prognosis. Gynecol Oncol 1988; 30: 347–58

    PubMed  CAS  Google Scholar 

  39. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimes (CHAP-5 versus CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157–68

    PubMed  CAS  Google Scholar 

  40. van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629–34

    PubMed  Google Scholar 

  41. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994; 53: 33–7

    PubMed  CAS  Google Scholar 

  42. Liu PC, Benjamin I, Morgan MA, et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997; 64(1): 4–8

    PubMed  CAS  Google Scholar 

  43. Munkarah AR, Hallum III AV, Morris M, et al. Prognostic significance of residual disease in patients with stage IV ovarian cancer. Gynecol Oncol 1997; 64: 13–7

    PubMed  CAS  Google Scholar 

  44. Cloven NC, Manetta A, Berman ML, et al. Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol 1999; 73: 137–9

    PubMed  CAS  Google Scholar 

  45. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience. Cancer 1993; 71(2 Suppl.): 606–14

    PubMed  CAS  Google Scholar 

  46. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Long-term survival in ovarian cancer. Eur J Cancer 1991; 27: 1367–72

    PubMed  CAS  Google Scholar 

  47. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991; 303: 884–93

    Google Scholar 

  48. Kristensen GB, Tropé C. Epithelial ovarian carcinoma. Lancet 1997; 349: 113–7

    PubMed  CAS  Google Scholar 

  49. McGuire WP, Hoskins JW, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    PubMed  CAS  Google Scholar 

  50. Piccart MJ, Bertelsen K, Stuart G, et al. Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience [abstract 1258]. Proc Am Assoc Clin Oncol 1997; 16: 352a

    Google Scholar 

  51. Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999; 10Suppl. 1: S87–92

    Google Scholar 

  52. Vermorken JB, van der Vijgh WJF, Klein I, et al. Pharmacoki-netics of free and total platinum species following rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 1986; 39: 136–44

    PubMed  CAS  Google Scholar 

  53. Reece PA, Stafford I, Russel J, et al. Creatinine clearance as a predictor of ultrafilterable platinum disposition in patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5: 304–9

    PubMed  CAS  Google Scholar 

  54. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol 1992; 19(5): 521–8

    PubMed  CAS  Google Scholar 

  55. Vermorken JB, van Groeningen CJ, Hart AAM, et al. Nephrotoxicity of cis-diamminedichloroplatinum(II): importance of dose, treatment regimen and infusion schedule. In: Vermorken JB. Cis-diamminedichloroplatinum(II) (cisplatin): clinical pharmacological studies [thesis]. Amsterdam: Free University, 1986

    Google Scholar 

  56. Gerritsen van der Hoop R, van der Burg MEL, ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990; 66: 1697–702

    Google Scholar 

  57. Tuxen MK, Hansen SW. Complications of treatment: neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994; 20: 191–214

    PubMed  CAS  Google Scholar 

  58. Thyss A, Saudes L, Otto A, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994; 12: 2121–5

    PubMed  CAS  Google Scholar 

  59. Trimble EL, Adams JD, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11(12): 2405–10

    PubMed  CAS  Google Scholar 

  60. Dorr RT. Pharmacology of the taxanes. Pharmacotherapy 1997; 17: 96–104S

    Google Scholar 

  61. Lichtman SM, Zaheer W, Gal D, et al. No increased risk of taxol in older patients [letter]. J Am Geriatr Soc 1996; 44: 472–4

    PubMed  CAS  Google Scholar 

  62. Rowinsky EK, Eisenhauer EA, Chaudry V, et al. Clinical toxicities encountered with paclitaxel (Taxol®). Semin Oncol 1993; 20Suppl. 3: 1–15

    PubMed  CAS  Google Scholar 

  63. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1992; 10: 1263–8

    Google Scholar 

  64. Gogas H, Shapiro F, Aghajanian C, et al. The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol Oncol 1996; 61(1): 22–6

    PubMed  CAS  Google Scholar 

  65. McGuire WP, Rowinsky EK, Rosenheim NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–9

    PubMed  CAS  Google Scholar 

  66. Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-l,l-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 1984; 44: 1693–7

    PubMed  CAS  Google Scholar 

  67. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748–56

    PubMed  CAS  Google Scholar 

  68. Egorin MJ, van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine(l,l-cyclobutane-dicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432–8

    PubMed  CAS  Google Scholar 

  69. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573–80

    PubMed  CAS  Google Scholar 

  70. Neijt JP, Engelholm SA, Tuxen M, et al. Paclitaxel-cisplatin vs paclitaxel-carboplatin in previously untreated ovarian cancer [abstract 312O]. Ann Oncol 1998; 9Suppl. 4: 65

    Google Scholar 

  71. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III study of cisplatin (cis)/paclitaxel (pac) versus carboplatin (carbo)/pac in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158) [abstract 1373]. Proc Am Assoc Clin Oncol 1999; 18: 356a

    Google Scholar 

  72. Du Bois A, Lueck HJ, Meier W, et al. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial [abstract 1374]. Proc Am Assoc Clin Oncol 1999; 18: 356a

    Google Scholar 

  73. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Ocol 1997; 15: 193–8

    CAS  Google Scholar 

  74. Muggia FM, Braly PS, Brady MF, et al. Phase III of cisplatin or paclitaxel, versus their combination in suboptimal stage III and I epithelial ovarian cancer: Gynecologic Oncology Group study #132 [abstract 1257]. Proc Am Assoc Clin Oncol 1997; 16: 352a

    Google Scholar 

  75. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998; 352: 1571–6

    Google Scholar 

  76. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistent epithelial ovarian cancer. J Clin Oncol 1994; 12: 60–3

    PubMed  CAS  Google Scholar 

  77. Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405–10

    PubMed  CAS  Google Scholar 

  78. Seymour MT, Mansi JL, Gallagher CJ, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191–5

    PubMed  CAS  Google Scholar 

  79. Moore DH, Valea F, Crumpler LS, et al. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol Oncol 1993; 51(1): 109–12

    PubMed  CAS  Google Scholar 

  80. Vergote I, Himmelmann A, Frankendal B, et al. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol Oncol 1992; 47(3): 282–6

    PubMed  CAS  Google Scholar 

  81. Manetta A, Tewari K, Podczaski ES. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol 1997; 66: 20–6

    PubMed  CAS  Google Scholar 

  82. Rustin GJS, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 1997; 15: 172–6

    PubMed  CAS  Google Scholar 

  83. Kjorstad K, Harris A, Bertelsen K, et al. A multicenter phase II study of carboplatin in advanced ovarian carcinoma: final report. Ann Oncol 1992; 3: 217–22

    PubMed  CAS  Google Scholar 

  84. Wils JA, van Geuns H, Wals J, et al. Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony-stimulating factor) in relapsed ovarian cancer: a study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Anticancer Drugs 1997; 8: 432–5

    PubMed  CAS  Google Scholar 

  85. Colleoni M, Sgarbossa G, Nelli P, et al. Weekly carboplatin in elderly patients with advanced ovarian cancer. Oncology Rep 1996; 3: 277–9

    CAS  Google Scholar 

  86. Vermorken JB, Bolis G, van Rijswijk REN, et al. High-dose regimens with epirubicin in ovarian cancer. Semin Oncol 1994; 21Suppl. 1: 17–22

    PubMed  CAS  Google Scholar 

  87. Sørensen P, Pfeiffer P, Bertelsen K. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. Gynecol Oncol 1995; 56(1): 75–8

    PubMed  Google Scholar 

  88. Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10(2): 243–8

    PubMed  CAS  Google Scholar 

  89. Willemse PHB, van der Burg MEL, van der Gaast A, et al. Ifosfamide given as a 24-h infusion with mesna in patients with recurrent ovarian cancer: preliminary results. Cancer Chemother Pharmacol 1990; 26 Suppl.: S51–4

    PubMed  Google Scholar 

  90. Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1672–6

    PubMed  CAS  Google Scholar 

  91. Thigpen JT, Blessing JA, Ball H, et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994; 12(9): 1748–53

    PubMed  CAS  Google Scholar 

  92. Einzig AL, Wiernik PH, Sasloff J, et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748–53

    PubMed  CAS  Google Scholar 

  93. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12(12): 2654–66

    PubMed  CAS  Google Scholar 

  94. Fenelly D, Aghajanian C, Shapiro F, et al. Phase I and pharma-cologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187–92

    Google Scholar 

  95. Kaye SB, Piccart M, Aapro M, et al. Phase II trials of docetaxel (Taxotere®) in advanced ovarian cancer: an updated over view. Eur J Cancer 1997; 33: 2167–70

    PubMed  CAS  Google Scholar 

  96. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′ difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530–3

    PubMed  CAS  Google Scholar 

  97. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gem-citabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89–93

    PubMed  CAS  Google Scholar 

  98. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14(9): 2546–51

    PubMed  CAS  Google Scholar 

  99. Rothenberg ML, Liu PY, Nahhas WA, et al. A phase II trial of vinorelbine in relapsed and refractory ovarian cancer: a Southwest Oncology Group study (SWOG-9324) [abstract 1480]. Proc Am Soc Clin Oncol 1999; 18: 383a

    Google Scholar 

  100. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056–61

    PubMed  CAS  Google Scholar 

  101. Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14(5): 1552–7

    PubMed  CAS  Google Scholar 

  102. Ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol, 1997; 15: 2183–93

    PubMed  Google Scholar 

  103. Safra T, Jeffers S, Groshen S, et al. Doxil® in platinum-refractory epithelial ovarian cancer: results from three consecutive phase I/II studies [abstract 1248]. Proc Am Assoc Clin Oncol 1997; 16: 349a

    Google Scholar 

  104. Gordon AN, Hainsworth J, Moore M, et al. Doxil® (doxorubicin Hcl liposome injection) in the treatment of patients with refractory advanced epithelial ovarian carcinoma: results of an interim analysis [abstract 1345]. Proc Am Assoc Clin Oncol 1998; 17: 17

    Google Scholar 

  105. Wils J, Lalisang R, Erdkamp F, et al. Docetaxel (T), epirubicin (E) and cisplatinum (P) with G-CSF (lenograstim) in patients with advanced ovarian cancer [abstract 1454]. Proc Am Assoc Clin Oncol 1998; 17

    Google Scholar 

  106. Blackledge G, Lawton F, Redman C, et al. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. BMJ 1989; 59: 650–3

    CAS  Google Scholar 

  107. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389–93

    PubMed  CAS  Google Scholar 

  108. Stanhope CR, Smith JP, Rutledge F. Second trial drugs in ovarian cancer. Gynecol Oncol 1977; 5: 52–8

    PubMed  CAS  Google Scholar 

  109. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55: S142–50

    Google Scholar 

  110. Goldberg JM, Piver MS, Hempling RE, et al. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1996; 63: 312–7

    PubMed  CAS  Google Scholar 

  111. van der Vange N, Greggi S, Burger CW, et al. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995; 34(6): 813–20

    PubMed  Google Scholar 

  112. Parmar H, Philips RH, Rustin G, et al. Therapy of advanced ovarian cancer with D-trp-6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother 1988; 42: 531–8

    PubMed  CAS  Google Scholar 

  113. Kavanagh JJ, Roberts W, Townsend P, et al. Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 1989; 7: 115–8

    PubMed  CAS  Google Scholar 

  114. Ron IG, Wigler N, Merimsky O, et al. A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest 1995; 13(3): 272–5

    PubMed  CAS  Google Scholar 

  115. Lind MJ, Cantwell BMJ, Millward MJ, et al. A phase II study of goserelin (Zoladex) in relapsed ovarian cancer. Br J Cancer 1992; 65: 621–3

    PubMed  CAS  Google Scholar 

  116. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemotherapy resistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 1957–68

    PubMed  CAS  Google Scholar 

  117. van der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995; 5: 301–5

    Google Scholar 

  118. Veenhof CH, van der Burg ME, Nooy M, et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma. Eur J Cancer 1994; 30A(5): 697–8

    PubMed  CAS  Google Scholar 

  119. Tumolo S, Rao BR, van der Burg ME, et al. Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer 1994; 30A(7): 911–4

    PubMed  CAS  Google Scholar 

  120. Weiner SA, Alberts DS, Surwitt EA, et al. Tamoxifen therapy in recurrent epithelial ovarian cancer. Gynecol Oncol 1987; 27: 208–13

    PubMed  CAS  Google Scholar 

  121. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen (a Gynecologic Oncology Group study of second-line therapy in 105 patients). Cancer 1991; 68: 269–71

    PubMed  CAS  Google Scholar 

  122. Gore ME, Fryatt I, Wiltshaw E, et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207–11

    PubMed  CAS  Google Scholar 

  123. Colombo N, Marzola M, Parma G, et al. Paclitaxel versus CAP (cyclophosphamide, adriamycine, cisplatin) in recurrent platinum sensitive ovarian cancer: a randomized phase II study [abstract 751]. Proc Am Soc Clin Oncol 1996; 15: 279

    Google Scholar 

  124. Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol 1996; 60: 393–6

    PubMed  CAS  Google Scholar 

  125. van Rijswijk REN, Tognon G, Burger CW, et al. The effect of chemotherapy on the components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. Int J Gynecol Cancer 1994; 4: 52–60

    PubMed  Google Scholar 

  126. Cohen CJ, Rahaman J. Endometrial cancer: management of high-risk and recurrence including the tamoxifen controversy. Cancer 1995; 76: 2044–52

    PubMed  CAS  Google Scholar 

  127. Fornander T, Rurqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989; 1: 117–20

    PubMed  CAS  Google Scholar 

  128. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NASBP) B-14. J Natl Cancer Inst 1994; 86: 527–37

    PubMed  CAS  Google Scholar 

  129. Creasman WT. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 1997; 24Suppl. 1: S1–140–50

    PubMed  CAS  Google Scholar 

  130. Bokhman JV. Two pathogenetic types of endometrial cancer. Gynecol Oncol 1983; 15: 10–7

    PubMed  CAS  Google Scholar 

  131. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995; 75 Suppl.: 270–94

    PubMed  CAS  Google Scholar 

  132. Corn BW, Dunton CJ, Carlson JA, et al. National trends in the surgical staging of corpus cancer: a pattern-of-practice survey. Obstet Gynecol 1997; 90: 628–31

    PubMed  CAS  Google Scholar 

  133. Martin-Hirsch PL, Lilford RJ, Jarvis GL. Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 1996; 65: 201–7

    PubMed  CAS  Google Scholar 

  134. Morrow CP, Bundy BN, Homesley HD. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 36: 166–71

    PubMed  CAS  Google Scholar 

  135. Moore TD, Phillips PH, Nerenstone SR, et al. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 1991; 9: 1071–88

    PubMed  CAS  Google Scholar 

  136. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma: a review of clinical observations. Acta Obstet Gynecol Scand 1984; 63: 441–50

    PubMed  CAS  Google Scholar 

  137. Thigpen T, Blessing J, Hatch K. A randomized trial of medroxyprogesterone acetate (MPA) 200mg versus 1000mg daily in advanced or recurrent endometrial carcinoma [abstract]. Proc Am Soc Clin Oncol 1991; 10: 185

    Google Scholar 

  138. Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol-acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1996; 14: 357–61

    PubMed  CAS  Google Scholar 

  139. Rendina GM, Donadio C, Fabri M, et-al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1984; 17: 285–91

    PubMed  CAS  Google Scholar 

  140. De Vriese G, Bonte J. Possible role of goserelin, an LH-RH agonist in the treatment of gynaecological cancers. Eur J Gynaecol Oncol 1993; 14: 187–91

    PubMed  Google Scholar 

  141. Slavik M, Petty WM, Blessing JA, et al. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1984; 68: 809–11

    PubMed  CAS  Google Scholar 

  142. Edmonson JH, Krook JE, Hilton JF, et al. Ineffectiveness of tamoxifen in advanced endometrial carcinoma after failure of progestin therapy. Cancer Treat Rep 1986; 70: 1019–20

    PubMed  CAS  Google Scholar 

  143. Muss HB. Chemotherapy of metastatic endometrial cancer. Semin Oncol 1994; 21: 107–13

    PubMed  CAS  Google Scholar 

  144. Thigpen T, Blessing J, Homesley H, et al. Phase III trial of doxorubicin +/- cisplatin in advanced or recurrent endome trial carcinoma: a Gynecologic Oncology Group (GOG) study [abstract]. Proc Am Soc Clin Oncol 1993; 12: 261

    Google Scholar 

  145. Aapro M, Bolis G, Chevallier B, et al. An EORTC-GCCG randomized phase II trial of doxorubicin (DOX) versus DOX-cisplatin (CDDP) in endometrial carcinoma [abstract 885]. Proc Am Soc Clin Oncol 1994; 13: 275

    Google Scholar 

  146. Burke TW, Munkarah A, Kavanagh JJ, et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol Oncol 1993; 51: 397–400

    PubMed  CAS  Google Scholar 

  147. Green III JB, Green S, Alberts DS, et al. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990; 75: 696–700

    PubMed  Google Scholar 

  148. Lissoni A, Zanetta G, Losa G, et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996; 7: 861–3

    PubMed  CAS  Google Scholar 

  149. Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 278–81

    PubMed  CAS  Google Scholar 

  150. Price FV, Edwards RP, Kelley JL, et al. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 1997; 24Suppl. 15: S15–78–82

    PubMed  CAS  Google Scholar 

  151. Martin LM, Parker SL, Wingo PA, et al. Cervical cancer incidence and screening status report on women in the United States. Cancer Pract 1996; 4: 130–4

    PubMed  CAS  Google Scholar 

  152. International Federation of Gynecology and Obstetrics. Staging announcement. FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer 1995; 5: 319

    Google Scholar 

  153. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535–40

    PubMed  CAS  Google Scholar 

  154. Vermorken JB. The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer 1993; 3: 129–42

    PubMed  Google Scholar 

  155. Thigpen T, Vance RB, Khansur T. Carcinoma of the uterine cervix: current status and future directions. Semin Oncol 1994; 21Suppl. 2: 43–54

    PubMed  CAS  Google Scholar 

  156. Eisenhauer EA, Vermorken JB. New drugs in gynecologic oncology. Curr Opin Oncol 1996; 8: 408–14

    PubMed  CAS  Google Scholar 

  157. Bonomi P, Blessing JA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079–85

    PubMed  CAS  Google Scholar 

  158. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1988; 32: 198–202

    Google Scholar 

  159. McGuire III WP, Arsenau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1462–8

    PubMed  Google Scholar 

  160. Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990; 39: 332–6

    PubMed  CAS  Google Scholar 

  161. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 15: 165–71

    PubMed  CAS  Google Scholar 

  162. Vermorken JB, Colombo N, van der Burg MEL, et al. Combination chemotherapy of bleomycin (B), vindesine (E), mito-mycin (M), and cisplatin (BEMP) versus single-agent cisplatin (P) in disseminated squamous cell carcinoma of the uterine cervix: a phase III trial [abstract]. Ann Oncol 1992; 3Suppl. 5: 103

    Google Scholar 

  163. Kearn J, Tropé C, Sundfoer K, et al. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol 1996; 60: 387–92

    Google Scholar 

  164. Vermorken JB, Mangioni C, van der Burg MEL, et al. EORTC-GCCG phase II trials in disseminated cancer of the uterine cervix. Ginecol Med Reprod 1985; 10: 125–31

    Google Scholar 

  165. Potter ME, Hatch KD, Potter MY, et al. Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 1989; 63: 1283–6

    PubMed  CAS  Google Scholar 

  166. Alberts DS, Martimbeau PW, Surwit EA, et al. Mitomycin C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix. Cancer Clin Trials 1981; 4: 313–6

    PubMed  CAS  Google Scholar 

  167. Hoskins PJ, Blake PR. Cisplatin, methotrexate and bleomycin for carcinoma of the cervix: the influence of presentation and previous treatment upon response. Int J Gynecol Cancer 1991; 1: 75–80

    Google Scholar 

  168. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339–48

    PubMed  CAS  Google Scholar 

  169. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137–43

    PubMed  CAS  Google Scholar 

  170. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144–53

    PubMed  CAS  Google Scholar 

  171. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154–61

    PubMed  CAS  Google Scholar 

  172. Sturgeon SR, Brinton LA, Devesa SS, et al. In situ and invasive vulvar cancer incidence trends (1973-1987). Am J Obstet Gynecol 1992; 166: 1482–5

    PubMed  CAS  Google Scholar 

  173. Hildesheim A, Han CL, Brinton LA, et al. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 1997; 90(5): 748–54

    PubMed  CAS  Google Scholar 

  174. Homesley HD. Management of vulvar cancer. Cancer 1995; 76: 2159–70

    PubMed  CAS  Google Scholar 

  175. Durrant KR, Mangioni C, Lacave AJ, et al. Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG). Gynecol Oncol 1990; 37: 359–62

    PubMed  CAS  Google Scholar 

  176. Benedetti-Panici P, Greggi S, Scambia G, et al. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol 1993; 50: 49–53

    PubMed  CAS  Google Scholar 

  177. Scheistroen M, Tropé C. Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva. Acta Oncol 1993; 32: 657–61

    PubMed  CAS  Google Scholar 

  178. Roberts WS, Hoffman MS, Kavanagh JJ, et al. Further experience with radiation therapy and concomitant intravenous chemotherapy in advanced carcinoma of the lower female genital tract. Gynecol Oncol 1991; 43: 233–6

    PubMed  CAS  Google Scholar 

  179. Eifel PJ, Morris M, Burke TW, et al. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva. Gynecol Oncol 1995; 59: 51–6

    PubMed  CAS  Google Scholar 

  180. Cunningham MJ, Goyer RP, Gibbons SK, et al. Primary radiation, cisplatin, and 5-fluorouracil for advanced squamous carcinoma of the vulva. Gynecol Oncol 1997; 66: 258–61

    PubMed  CAS  Google Scholar 

  181. Berek JS, Heaps JM, Fu YS, et al. Concurrent cisplatin and 5-fluorouracil chemotherapy and radiation therapy for advanced-stage squamous carcinoma of the vulva. Gynecol Oncol 1991; 42: 197–201

    PubMed  CAS  Google Scholar 

  182. Koh WJ, Wallace III HJ, Greer BE, et al. Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. Int J Radiat Oncol Biol Phys 1993; 26: 809–16

    PubMed  CAS  Google Scholar 

  183. Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol 1996; 61: 321–7

    PubMed  CAS  Google Scholar 

  184. Lupi G, Raspagliesi F, Zucali R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma. Cancer 1996; 77: 1472–8

    PubMed  CAS  Google Scholar 

  185. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst 1993; 85: 1580–4

    PubMed  CAS  Google Scholar 

  186. Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7: 189–95

    PubMed  CAS  Google Scholar 

  187. Roila F, Tonato M, Basurto C, et al. Anti-emetic activity of high-dose of metoclopramide combined with methylprednis-olone versus metoclopramide alone in cisplatin-treated cancer patients. J Clin Oncol 1987; 5: 141–9

    PubMed  CAS  Google Scholar 

  188. Walsh SJ, Begg CB, Carbone PP. Cancer chemotherapy in the elderly. Semin Oncol 1989; 16: 66–75

    PubMed  CAS  Google Scholar 

  189. Cascinu S, Del Ferro E, Catalano G. Toxicity and therapeutic response to chemotherapy in patients aged 70 years or older with advanced cancer. Am J Clin Oncol 1996; 19: 371–4

    PubMed  CAS  Google Scholar 

  190. De Mulder PHM, Seynaeve C, Vermorken JB, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40

    PubMed  Google Scholar 

  191. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998; 16: 2937–42

    Google Scholar 

  192. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7: 108–14

    PubMed  CAS  Google Scholar 

  193. Pater JL, Lofters WS, Zee B, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997; 8: 181–5

    PubMed  CAS  Google Scholar 

  194. Laurell G, Borg E. Ototoxicity of cisplatin in gynaecological cancer patients. Scand Audiol 1988; 17: 241–7

    PubMed  CAS  Google Scholar 

  195. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results from a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2102–12

    Google Scholar 

  196. Hospers GAP, Eisenhauer EA, de Vries EGE. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents: a review, indications for use and prospects. Br J Cancer 1999; 80: 629–38

    PubMed  CAS  Google Scholar 

  197. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997; 80: 1134–40

    PubMed  CAS  Google Scholar 

  198. Planting AST, Catimel G, de Mulder PHM, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 1999; 10: 698–700

    Google Scholar 

  199. Smyth I, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind randomised trial. Ann Oncol 1997; 8: 569–73

    PubMed  CAS  Google Scholar 

  200. Markman M, Reichman B, Hakes T, et al. The use of recombinant human erythropoietin to prevent carboplatin-induced anemia. Gynecol Oncol 1993; 49: 172–6

    PubMed  CAS  Google Scholar 

  201. Kurz Ch, Marth Ch, Windbichler G, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997; 65: 461–6

    PubMed  CAS  Google Scholar 

  202. Lipschutz DA. Age-related declines in hematopoietic reserve capacity. Semin Oncol 1995; 22Suppl. 1: 3–5

    Google Scholar 

  203. Tjan-Heijnen VCG, Manegold C, Buchholz E, et al. Reduction of chemotherapy-induced febrile leukopenia by ciprofloxacin and roxithromycin in small cell lung cancer (SCLC) patients: an EORTC phase III study [abstract 1808]. Proc Am Soc Clin Oncol 1999; 18: 469a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology/Oncology, University Hospital Maastricht, Maastricht, The Netherlands

    Ruud E. N. van Rijswijk

  2. Department of Medical Oncology, University Hospital Antwerp, Antwerp, Belgium

    Jan B. Vermorken

Authors
  1. Ruud E. N. van Rijswijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan B. Vermorken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan B. Vermorken.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Rijswijk, R.E.N., Vermorken, J.B. Drug Therapy for Gynaecological Cancer in Older Women. Drugs & Aging 17, 13–32 (2000). https://doi.org/10.2165/00002512-200017010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200017010-00002

Keywords

Search

Navigation